- Investing Ideas
- /
- Australian Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Australian Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Results
60
Strong Balance Sheet Stocks: companies with a Health score of at least 4, ordered by Health score.
60 companies
Clinuvel Pharmaceuticals
Market Cap: AU$529.4m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$10.74
7D
5.7%
1Y
-29.3%
Vita Life Sciences
Market Cap: AU$100.4m
A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.
VLS
AU$1.83
7D
2.2%
1Y
-21.7%
Little Green Pharma
Market Cap: AU$36.3m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.13
7D
4.2%
1Y
-10.7%
Alterity Therapeutics
Market Cap: AU$53.3m
Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.
ATH
AU$0.007
7D
0%
1Y
0%
Firebrick Pharma
Market Cap: AU$16.8m
Engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia.
FRE
AU$0.08
7D
1.3%
1Y
50.9%
Invion
Market Cap: AU$8.1m
A clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia.
IVX
AU$0.10
7D
-4.8%
1Y
-80.0%
LTR Pharma
Market Cap: AU$68.8m
A biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia.
LTP
AU$0.35
7D
7.6%
1Y
24.6%
Immutep
Market Cap: AU$349.3m
A late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia.
IMM
AU$0.24
7D
4.3%
1Y
-31.9%
Algorae Pharmaceuticals
Market Cap: AU$8.4m
A pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand.
1AI
AU$0.005
7D
0%
1Y
-50.0%
Arovella Therapeutics
Market Cap: AU$97.1m
A biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally.
ALA
AU$0.08
7D
14.3%
1Y
-23.8%
Neuren Pharmaceuticals
Market Cap: AU$1.2b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$11.13
7D
23.0%
1Y
-45.4%
Argenica Therapeutics
Market Cap: AU$92.9m
A biotechnology company, engages in the research and development of neuroprotective therapeutic drug in Australia.
AGN
AU$0.69
7D
3.7%
1Y
6.9%
Radiopharm Theranostics
Market Cap: AU$53.7m
Engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs.
RAD
AU$0.023
7D
21.1%
1Y
-50.0%
Nyrada
Market Cap: AU$25.2m
A pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases.
NYR
AU$0.12
7D
17.3%
1Y
9.5%
Hexima
Market Cap: AU$2.2m
Does not have significant operations.
HXL
AU$0.013
7D
0%
1Y
-18.8%
Invex Therapeutics
Market Cap: AU$5.3m
A biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia.
IXC
AU$0.07
7D
4.5%
1Y
-17.6%
Biotron
Market Cap: AU$3.3m
A biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.
BIT
AU$0.003
7D
-25.0%
1Y
-95.9%
Actinogen Medical
Market Cap: AU$94.0m
A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.
ACW
AU$0.029
7D
0%
1Y
-12.1%
Cleo Diagnostics
Market Cap: AU$48.2m
A medical diagnostics and devices company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia.
COV
AU$0.44
7D
18.9%
1Y
120.0%
Clarity Pharmaceuticals
Market Cap: AU$519.0m
A clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States.
CU6
AU$1.75
7D
14.8%
1Y
-34.2%
EZZ Life Science Holdings
Market Cap: AU$68.9m
Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and internationally.
EZZ
AU$1.45
7D
10.7%
1Y
70.6%
Percheron Therapeutics
Market Cap: AU$10.9m
Engages in the research and development of novel antisense pharmaceuticals in Australia.
PER
AU$0.011
7D
10.0%
1Y
-85.5%
Race Oncology
Market Cap: AU$177.2m
A clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments.
RAC
AU$0.98
7D
1.0%
1Y
-35.1%
Tissue Repair
Market Cap: AU$14.2m
A clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia.
TRP
AU$0.24
7D
-2.0%
1Y
6.7%
Immuron
Market Cap: AU$15.6m
A biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.
IMC
AU$0.065
7D
8.3%
1Y
-35.0%
Orthocell
Market Cap: AU$343.6m
A regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union.
OCC
AU$1.48
7D
10.1%
1Y
283.1%
Amplia Therapeutics
Market Cap: AU$20.2m
A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.
ATX
AU$0.053
7D
-1.9%
1Y
-37.6%
Emyria
Market Cap: AU$14.2m
Engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia.
EMD
AU$0.031
7D
34.8%
1Y
-47.5%
Island Pharmaceuticals
Market Cap: AU$32.7m
A drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections in Australia and the United States of America.
ILA
AU$0.17
7D
16.7%
1Y
191.7%
NeuroScientific Biopharmaceuticals
Market Cap: AU$5.1m
Engages in the research and development of novel peptide-based pharmaceutical products.
NSB
AU$0.035
7D
0%
1Y
-42.6%
PYC Therapeutics
Market Cap: AU$550.9m
A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
PYC
AU$1.00
7D
-2.4%
1Y
4.2%
Vitrafy Life Sciences
Market Cap: AU$69.6m
Provides cryopreservation solutions in Australia.
VFY
AU$1.23
7D
13.9%
1Y
n/a
Noxopharm
Market Cap: AU$20.2m
A biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia.
NOX
AU$0.069
7D
-1.4%
1Y
-1.4%
Cryosite
Market Cap: AU$38.8m
Provides outsourced clinical trials logistic services in Australia.
CTE
AU$0.80
7D
5.3%
1Y
15.2%
Chimeric Therapeutics
Market Cap: AU$8.1m
A clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia.
CHM
AU$0.004
7D
0%
1Y
-88.2%
Starpharma Holdings
Market Cap: AU$40.4m
A biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide.
SPL
AU$0.098
7D
8.9%
1Y
-24.6%